We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Alnylam Pharmaceuticals (ALNY - Free Report) will report quarterly loss of $0.56 per share in its upcoming release, pointing to a year-over-year decline of 250%. It is anticipated that revenues will amount to $588.18 million, exhibiting an increase of 19% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 4.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Alnylam metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues- Product revenues, net' of $464.60 million. The estimate suggests a change of +27.2% year over year.
The combined assessment of analysts suggests that 'Revenues- Royalty revenue' will likely reach $30.71 million. The estimate indicates a year-over-year change of +189.1%.
The consensus estimate for 'Revenues- Net revenues from research collaborators' stands at $93.37 million. The estimate indicates a year-over-year change of -21.2%.
Analysts' assessment points toward 'Net Product Revenues- Oxlumo' reaching $44.67 million. The estimate indicates a change of +4.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Product Revenues- Givlaari' should arrive at $67.46 million. The estimate indicates a change of +16.2% from the prior-year quarter.
It is projected by analysts that the 'Net Product Revenues- Amvuttra' will reach $300.02 million. The estimate points to a change of +53.7% from the year-ago quarter.
The consensus among analysts is that 'Net Product Revenues- Onpattro' will reach $51.23 million. The estimate indicates a year-over-year change of -26%.
Alnylam shares have witnessed a change of -5.6% in the past month, in contrast to the Zacks S&P 500 composite's -0.8% move. With a Zacks Rank #3 (Hold), ALNY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Alnylam Pharmaceuticals (ALNY - Free Report) will report quarterly loss of $0.56 per share in its upcoming release, pointing to a year-over-year decline of 250%. It is anticipated that revenues will amount to $588.18 million, exhibiting an increase of 19% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 4.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Alnylam metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues- Product revenues, net' of $464.60 million. The estimate suggests a change of +27.2% year over year.
The combined assessment of analysts suggests that 'Revenues- Royalty revenue' will likely reach $30.71 million. The estimate indicates a year-over-year change of +189.1%.
The consensus estimate for 'Revenues- Net revenues from research collaborators' stands at $93.37 million. The estimate indicates a year-over-year change of -21.2%.
Analysts' assessment points toward 'Net Product Revenues- Oxlumo' reaching $44.67 million. The estimate indicates a change of +4.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Product Revenues- Givlaari' should arrive at $67.46 million. The estimate indicates a change of +16.2% from the prior-year quarter.
It is projected by analysts that the 'Net Product Revenues- Amvuttra' will reach $300.02 million. The estimate points to a change of +53.7% from the year-ago quarter.
The consensus among analysts is that 'Net Product Revenues- Onpattro' will reach $51.23 million. The estimate indicates a year-over-year change of -26%.
View all Key Company Metrics for Alnylam here>>>
Alnylam shares have witnessed a change of -5.6% in the past month, in contrast to the Zacks S&P 500 composite's -0.8% move. With a Zacks Rank #3 (Hold), ALNY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>